Cancer Cure Now

American Metabolic Laboratories in Hollywood, Florida, offers a patented "Cancer Profile" test which measure 7 different markers including HCG.  The test costs $296 USD as of December 2006.

Invented by Dr. Emil K. Schandl, a clinical biochemist and oncobiologist, this panel of blood tests is said to be 93% accurate at detecting even very early cancers.

"Most of the current procedures that look for tumors examine various organs via X-rays, CAT scans, MRI, nuclear medicinal radiation or surgery," says Schandl. "I always thought that there must be a less-damaging, less-invasive way of looking at a person's insides. That is how I conceived the idea of developing a cancer profile."

Using a battery of several different tests provides greater accuracy than relying on only one marker, since Schandl's own studies on diagnosed cancer patients found that 32% had normal HCG levels.

The first four tests are definite tumor markers, while the last two are suggestive of health problems conducive to and/or associated with malignancy.

HCG (IRMA) (intact HCG) and HCG (IMM) : (Nicked beta and beta core subunits)  human chorionic gonadotropic hormone, a pregnancy hormone also elevated in 68% of cancer patients. PHI : phosphohexoses isomerase enzyme that regulates anaerobic metabolism, can be elevated due to cancer or an acute heart, liver, muscle disease, or acute viral infection.

If an acute condition can be ruled out, cancer may be the cause of the elevated result. Elevated in 36% of cancer patients.

CEA : carcinoembryonic antigen, a cancer antigen. This test was originally developed to monitor colon and rectal cancers, but is also elevated in other malignancies. Elevated in 51% of cancer patients.

GGTP : gamma-glutamyl transpaptidase, an enzyme for monitoring the liver and bile system. The liver is the chief detoxifying organ and is often affected in malignancies. Elevated in 39% of cancer patients.

TSH : thyroid stimulating hormone which indirectly measures thyroid activity (when it is low the thyroid is over active and when it is high the thyroid is under active). Hypothyroidism is common in cancer patients.

DHEA-S : dehydroepiandrosterone sulfate, the adrenal hormone which boosts immune response and stress resistance. Low DHEA is common in cancer patients. It is claimed that this test can detect pre-malignant conditions that will take up to a decade to develop into symptomatic cancers.

When given to members of the general public, the test gives many false positives, up to 40%. However, considering that 1 out of every 2.5 Americans develop cancer during their lifetimes, perhaps the test is accurately detecting pre-malignant states.